Join the Multiple Myeloma group to help and get support from people like you.
Multiple Myeloma News
Related terms: Cancer, Malignant Plasmacytoma, Cancer, Multiple Myeloma, Cancer, Plasma Cell Dyscrasia, Cancer, Plasma Cell Myeloma, Malignant Plasmacytoma, Myeloma, Multiple, Plasma Cell Dyscrasia, Plasma Cell Myeloma, Plasmacytoma of Bone, Kahler's disease
His Cancer Journey Shows Health Dangers Firefighters Face
FRIDAY, May 10, 2024 – For 14 years, David Perez fought fires in South Florida, thinking he was in peak physical shape. Then a routine physical turned up anomalies in his blood work that turned his...
Persistent Sociodemographic Differences Seen in Use of AutoHCT for Multiple Myeloma
WEDNESDAY, May 8, 2024 – Sociodemographic differences persist in utilization of autologous hematopoietic cell transplantation (autoHCT) for multiple myeloma, according to a study published in the...
FDA Approves Abecma for Relapsed, Refractory Multiple Myeloma
TUESDAY, April 9, 2024 – The U.S. Food and Drug Administration has approved Abecma (idecabtagene vicleucel) as a personalized CAR T-cell therapy for triple-class exposed relapsed or refractory...
FDA Approves Carvykti for Patients with Relapsed or Refractory Multiple Myeloma Who Have Received at Least One Prior Line of Therapy
HORSHAM, PA (April 5, 2024) – Johnson & Johnson (NYSE: JNJ) announced today that the U.S. Food and Drug Administration (FDA) has approved CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) for the tr...
U.S. FDA Approves Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy
PRINCETON, N.J., & CAMBRIDGE, Mass.--(BUSINESS WIRE) April 05, 2024 – Bristol Myers Squibb (NYSE: BMY) and 2seventy bio, Inc. (Nasdaq: TSVT) have announced that on April 4, 2024, the U.S. Food and...
Survival 21 Percent a Year After ICU Discharge for Blood Cancer Patients
THURSDAY, March 21, 2024 – For hematologic malignancy (HM) patients admitted to the intensive care unit (ICU), survival is 49 percent at seven days and 21 percent at 12 months, according to a study...
Tecvayli (teclistamab-cqyv) Biweekly Dosing Approved by the U.S. FDA for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
HORSHAM, Pa., Feb. 20, 2024 /PRNewswire/ – Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for ...
Triplet Therapy Including Belamaf Prolongs Survival in Multiple Myeloma
FRIDAY, Feb. 9, 2024 – For patients with relapsed or refractory multiple myeloma (RRMM), triplet therapy of belantamab mafodotin (belamaf) plus bortezomib and dexamethasone (BVd) improves outcomes,...
FDA Warns of Rare Secondary Cancer Risk With CAR-T Therapies
WEDNESDAY, Jan. 24, 2024 (Healthday News) – The U.S. Food and Drug Administration has told drugmakers to add a boxed warning to a type of cancer treatment called CAR-T therapy, saying the treatment...
Risk Factors ID'd for Monoclonal Gammopathy of Undetermined Significance
FRIDAY, Jan. 19, 2024 – For individuals at increased risk for multiple myeloma, risk factors associated with mass spectrometry (MS) monoclonal gammopathy of undetermined significance (MGUS) include...
American Society of Hematology, Dec. 9 to 12
The annual meeting of the American Society of Hematology was held from Dec. 9 to 12 in San Diego and attracted participants from around the world, including hematology specialists as well as clinical...
Robust Score Can ID Infection Risk in Newly Diagnosed Multiple Myeloma
TUESDAY, Dec. 19, 2023 – A robust score can identify patients with newly diagnosed multiple myeloma (NDMM) at risk for severe infection/death, according to a study published online Dec. 7 in...
ASH: Daratumumab Beneficial for Patients With Multiple Myeloma
WEDNESDAY, Dec. 13, 2023 – For transplantation-eligible patients with newly diagnosed multiple myeloma, the addition of subcutaneous daratumumab combined with bortezomib, lenalidomide, and...
Racial, Ethnic Differences ID'd for Idecabtagene Vicleucel in Multiple Myeloma
WEDNESDAY, Oct. 25, 2023 – There are some racial and ethnic differences in safety and response to standard of care (SOC) idecabtagene vicleucel (ide-cel) in patients with relapsed/refractory...
Diabetes More Prevalent in Black Patients With Multiple Myeloma
FRIDAY, Oct. 6, 2023 – Diabetes mellitus (DM) is more prevalent among Black patients with multiple myeloma (MM) and is associated with overall survival in MM, especially among White patients,...
Ask a question
To post your own question to this support group, sign in or create an account.